scispace - formally typeset
Patent

Anti-angiogenic compositions and methods of use

Reads0
Chats0
TLDR
In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
Abstract
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

read more

Citations
More filters
Patent

Coated implantable medical device

TL;DR: A coated implantable medical device as discussed by the authors includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent

Therapeutic inhibitor of vascular smooth muscle cells

TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
Patent

Medical devices and applications of polyhydroxyalkanoate polymers

TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.
Patent

Silver implantable medical device

TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent

Drug coating with topcoat

TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.
References
More filters
Journal ArticleDOI

Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin

TL;DR: In this paper, the interaction between 23 anticancer drugs and hydroxypropyl-β-cyclodextrin (HPβCD) was studied by reversed phase charge-transfer thin-layer chromatography and the relative strength of interaction was calculated.
Journal ArticleDOI

Evaluation of poly(isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. I: Effect of formulation variables on physicochemical characteristics of nanoparticles

TL;DR: A factorial design was applied to evaluate the effect of formulation variables on physicochemical properties of poly(isobutylcyanoacrylate) nanoparticles and a wide range of molecular weight distribution was observed.
Journal ArticleDOI

Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer

TL;DR: Attempts were made to prolong the bioavailability of antimycobacterial drugs after a single administration of polylactic-co-glycolic acid (PLGA) co-polymer containing isoniazid, which ensured its sustained release up to 6 weeks.
Journal ArticleDOI

Drug release from a new family of biodegradable polyanhydrides

TL;DR: In this paper, the effect of copolymer properties (e.g., hydrophobicity, crystallinity, drug properties) and drug loading on drug release was investigated.
Patent

Use of inhibitors of plasminogen activators for the treatment of inflammations and wounds

TL;DR: The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds is discussed in this paper, which relates to inhibitors of urokinase, uPA or tPA.